(226) evaluated the anti-PD-1 checkpoint inhibitor nivolumab intravenously in patients with recurrent GBM in a phase I trial, both as monotherapy or in combination with CTLA-4 blocking mAb ipilimumab at different dose levels. This evidence concerns the gene CTLA4 and glioblastoma.